

## **EuResist Network**

### **Partnership and authorship regulation**

Partnership with the EuResist Network is offered by the *EuResist* Network Management Board to new partners of proved or potential scientific value.

The *EuResist* Network Management Board is composed by Francesca Incardona, Rolf Kaiser, Thomas Lengauer, Anders Sonnerborg and Maurizio Zazzi. It decides by absolute majority about invitations for partnership. It can, by absolute majority, decide to definitely renounce to convene one or more partners in office, without necessarily giving a justification.

Partnership is based on scientific collaboration and data sharing for mutual benefit.

Partners become members of the *EuResist* Network Scientific Board. The *EuResist* Network Scientific Board membership, powers and duties are detailed hereby in the “*EuResist* Network Scientific Board” chapter.

Reasons for partnership include either expanding the *EuResist* Integrated Data Base (EIDB) with valuable data or contributing to data analysis in scope with the EuResist Network aims or both. Partner’s activities and data are protected by the data and authorship policies detailed hereby in the “Contributing to *EuResist*” chapter.

Partners will have access to the EIDB for research proposals following the rules detailed hereby in the “Use of *EuResist* data” chapter.

### **1. *EuResist* Network Scientific Board**

#### **1.1 Members**

The *EuResist* Network Scientific Board is composed by the Management Board and by all the partners of the *EuResist* Network.

#### **1.2 Objectives and functions**

1. To suggest research proposal based on the use of the data stored in the EIDB.
2. To evaluate the scientific adequacy of research proposals, made by third parties, that require the access to the data stored in the EIDB. Each proposal that requires the use of the Data stored in the EIDB, coming from either a member of the Scientific Board and/or third parties, must be approved by the Scientific Board.
3. Decisions on approval or rejection of research proposals based on the EIDB are taken by simple majority.
4. The Scientific Board can be interrogated and answered by email but anyway on the basis of a written document.

5. It is duty of the Scientific Board to provide approval or rejection of proposals within 15 days from receipt.

## **2. Contributing to EuResist**

### **2.1 Data integration**

The task of integrating new data from partners into the EIDB will be carried out by the EuResist Network team with the collaboration of the data provider, limited to providing information on database platform and schema and sending data via the method agreed upon.

Integrating data ensures a quality control made by the EIDB administrator at the advantage of the contributing centre. Partners will receive quality control feedbacks from EuResist.

### **2.1 Data protection**

Data provided by a partner always remain the property of the partner.

Data are contributed by the partner solely for the development of the treatment response models that are the focus of the EuResist Network. Any other use is subject to information to and explicit approval by the partner

The partner reserves the right to have its data permanently removed from the EIDB at any moment without any need to justify this decision. Should this occur, the data are considered available only for pending papers and/or presentations already agreed upon, i.e. submitted for publication.

Should the EuResist Network GEIE end, each external dataset will be removed from the EIDB unless the partner explicitly requests that the data remain in the EIDB.

### **2.3 Authorship policy**

Authorship of publications using EIDB data is regulated as follows:

1. All individuals making a major contribution to a publication are acknowledged by the inclusion of the individual's name as an author. Major contribution is defined in agreement with the rules of the International Committee of Medical Journal Editors (ICMJE; website <http://www.icmje.org/index.html#authorship>).
2. The name of the individual who conceived the study and drafted the manuscript/abstract is listed as first author, with subsequent names listed in order of decreasing contribution.
3. Alternatively, an individual who makes a major contribution to a publication may opt to be listed as last author to identify the research group or unit in which the work was done even though that individual's overall contribution is not less than those of individuals listed earlier on the by-line.
4. Partners designate their representatives to be included as authors.
5. The number of names listed on the by-line as representatives of the data providers is obtained as the maximum number of authors allowed by the journal/congress minus the number of authors who contributed substantially to study conception and design, data analysis and interpretation, manuscript preparation and approval.
6. The priority list of data provider partners' representatives to be included as authors reflects the proportion of cases in the study contributed by each data provider partner.
7. Data provider partners' representatives not included as authors because the maximum number of names has been reached maintain their credits and are considered for authorship of future papers.

8. The *EuResist* Network should be listed as author by adding “the *EuResist* Network Study Group” after the last author on the by-line. Or, the *EuResist* Network should be acknowledged in the acknowledgement section by saying “This study benefited from data provided by *EuResist* Network EIDB”
9. All other contributors are listed in an acknowledgments section.

### **3. Ethics**

All the patient information contained in the EIDB and its future updates and upgrades is anonymised. Patients whose data have been included in the EIDB via the original data sources have signed an informed consent indicating their permission to use their own data for non-commercial purposes. *EuResist* itself does not deal with ethical permissions. Data providers have the responsibility to grant that local and national ethical committees have approved the individual databases for anonymised research purposes.

*EuResist* does not involve either storage or any work on biological samples. *EuResist* primary goal and additional research activities are limited to data handling and elaboration in agreement with the specific studies approved by the Scientific Board. Should any participant to any research proposal require ethical approval for the specific proposal it is understood that the individual participant would take care of this step locally.